← All diseases
Liver, kidneys and digestion
Fatty liver disease (MASH/NASH), advanced
Do you want to receive a message when there is new research about Liver Fat (MASH/NASH), advanced? This is possible with an account. Create a free account or log in.
Automatically tracked from PubMed and ClinicalTrials.gov, newest on top. Nothing ever disappears here: what you keep in your favorites remains findable. · RSS feed of this disease · only the strongest evidence
Read in plain language what each study is about? With Premium, a single sentence appears above each publication explaining what was studied — and you'll be notified as soon as new research on Liver Steatosis (MASH/NASH), Advanced is available. View what Premium costs.
Publications and studies (2550)
- Sequential algorithm to stratify liver fibrosis risk in overweight/obese metabolic dysfunction-associated fatty liver disease. (2023/01/06) ♡
- Review articleiA summary of what is known about a topic, written by experts. Not compiled according to fixed search rules, so the selection of studies may be biased. Effects of beer, wine, and baijiu consumption on non-alcoholic fatty liver disease: Potential implications of the flavor compounds in the alcoholic beverages. (2023/01/06) ♡
- Review articleiA summary of what is known about a topic, written by experts. Not compiled according to fixed search rules, so the selection of studies may be biased. Asprosin in health and disease, a new glucose sensor with central and peripheral metabolic effects. (2023/01/05) ♡
- Systematic reviewiAll research on one question is searched according to fixed rules and compared side by side, so that no studies with poor outcomes are missed. The relationship between glucose and the liver-alpha cell axis - A systematic review. (2023/01/05) ♡
- Commentary or editorialiAn expert's opinion or commentary, not new research. Communicating PNPLA3 genetic risk status for NAFLD among Mexican-origin men. (2023/01/04) ♡
- Using two-step cluster analysis to classify inpatients with primary biliary cholangitis based on autoantibodies: A real-world retrospective study of 537 patients in China. (2023/01/04) ♡
- SIMs score - method for quantification of metabolic syndrome, confirms co-founding factors of metabolic syndrome. (2023/01/04) ♡
- Commentary or editorialiAn expert's opinion or commentary, not new research. Transcriptomic profiling of hepatic tissues for drug metabolism genes in nonalcoholic fatty liver disease: A study of human and animals. (2023/01/04) ♡
- Genetic polymorphisms of Ca (2+) transport proteins and molecular chaperones in mitochondria-associated endoplasmic reticulum membrane and non-alcoholic fatty liver disease. (2023/01/04) ♡
- Increased plasma genistein after bariatric surgery could promote remission of NAFLD in patients with obesity. (2023/01/04) ♡
- Commentary or editorialiAn expert's opinion or commentary, not new research. Editorial: The liver as an endocrine organ: Hepatokines and ketone bodies, novel hormones to be acknowledged. (2023/01/04) ♡
- Systematic reviewiAll research on one question is searched according to fixed rules and compared side by side, so that no studies with poor outcomes are missed. Comparative efficacy of Chinese patent medicines for non-alcoholic fatty liver disease: A network meta-analysis. (2023/01/04) ♡
- Effects of Zhishi Daozhi Decoction on the intestinal flora of nonalcoholic fatty liver disease mice induced by a high-fat diet. (2023/01/04) ♡
- Prevalence of High-risk Nonalcoholic Steatohepatitis (NASH) in the United States: Results From NHANES 2017-2018. (2023/01/01) ♡
- Review articleiA summary of what is known about a topic, written by experts. Not compiled according to fixed search rules, so the selection of studies may be biased. Natural Foods for the Treatment of Nonalcoholic Fatty Liver Disease. (2023/01/01) ♡
- Osr1 regulates macrophage-mediated liver inflammation in nonalcoholic fatty liver disease progression. (2023/01/01) ♡
- Laboratory or animal researchiNo research in humans yet. Promising in a test tube or in mice unfortunately means nothing for patients. Inulin intervention attenuates hepatic steatosis in rats via modulating gut microbiota and maintaining intestinal barrier function. (2023/01/01) ♡
- Meta-analysisiAll studies on one question combined and calculated together. This is the strongest form of research that exists: a single loose study can be coincidence, dozens together much less so. The label says something about the design, not about the outcome — which can also be that something does NOT work. Statins for the Treatment of Nonalcoholic Fatty Liver Disease and Nonalcoholic Steatohepatitis: A Systematic Review and Meta-Analysis. (2023/01/01) ♡
- Integrative multi-omics unravels the amelioration effects of Zanthoxylum bungeanum Maxim. on non-alcoholic fatty liver disease. (2023/01/01) ♡
- Phytochemical gallic acid alleviates nonalcoholic fatty liver disease via AMPK-ACC-PPARa axis through dual regulation of lipid metabolism and mitochondrial function. (2023/01/01) ♡
- Review articleiA summary of what is known about a topic, written by experts. Not compiled according to fixed search rules, so the selection of studies may be biased. Sarcopenia in the Cirrhotic Patient: Current Knowledge and Future Directions. (2023/01/01) ♡
- Review articleiA summary of what is known about a topic, written by experts. Not compiled according to fixed search rules, so the selection of studies may be biased. Spectrum, Screening, and Diagnosis of Alcohol-related Liver Disease. (2023/01/01) ♡
- Caveolin-1 ameliorates acetaminophen-aggravated inflammatory damage and lipid deposition in non-alcoholic fatty liver disease via the ROS/TXNIP/NLRP3 pathway. (2023/01/01) ♡
- Review articleiA summary of what is known about a topic, written by experts. Not compiled according to fixed search rules, so the selection of studies may be biased. Preclinical models of non-alcoholic steatohepatitis leading to hepatocellular carcinoma. (2023/01/01) ♡
- Review articleiA summary of what is known about a topic, written by experts. Not compiled according to fixed search rules, so the selection of studies may be biased. Predicting disruptions to drug pharmacokinetics and the risk of adverse drug reactions in non-alcoholic steatohepatitis patients. (2023/01/01) ♡
- α-D-1,3-glucan from Radix Puerariae thomsonii improves NAFLD by regulating the intestinal flora and metabolites. (2023/01/01) ♡
- Effects of Aramchol in patients with nonalcoholic fatty liver disease (NAFLD). A systematic review and meta-analysis. (2023/01/01) ♡
- Review articleiA summary of what is known about a topic, written by experts. Not compiled according to fixed search rules, so the selection of studies may be biased. Natural Compounds as Integrative Therapy for Liver Protection against Inflammatory and Carcinogenic Mechanisms: From Induction to Molecular Biology Advancement. (2023/01/01) ♡
- Zuogui-Jiangtang-Qinggan-Fang alleviates high-fat diet-induced type 2 diabetes mellitus with non-alcoholic fatty liver disease by modulating gut microbiome metabolites-short chain fatty acid composition. (2023/01/01) ♡
- Review articleiA summary of what is known about a topic, written by experts. Not compiled according to fixed search rules, so the selection of studies may be biased. Therapeutic Potential of Herbal Medicine against Non-Alcoholic Fatty Liver Disease. (2023/01/01) ♡
- Laboratory or animal researchiNo research in humans yet. Promising in a test tube or in mice unfortunately means nothing for patients. [Zuogui Jiangtang Qinggan Prescription promotes recovery of intestinal mucosal barrier in mice with type 2 diabetes mellitus and nonalcoholic fatty liver disease by improving intestinal flora homeostasis]. (2023/01/01) ♡
- Increasing the efficiency of hypolipidemic therapy with the combined use of quercetin in patients with non-alcoholic fatty liver disease on the background of the metabolic syndrome. (2023/01/01) ♡
- Clinical trialiResearch in patients, without randomization between groups. Useful, but less certain than a randomized trial. Study on MAFLD-related Cirrhosis Prevention and Treatment Strategies (2023-11-18) ♡
- Clinical trialiResearch in patients, without randomization between groups. Useful, but less certain than a randomized trial. The Potential Value and Impact of Diagnostic Biomarkers for MAFLD Using Machine Learning Methods (2023-09-29) ♡
- Clinical trialiResearch in patients, without randomization between groups. Useful, but less certain than a randomized trial. Supplementation With Alpha-lipoic Acid and Silybum Marianum(LUDLEV®) for the Improvement of Fatty Liver Disease (2023-06-22) ♡
- Clinical trialiResearch in patients, without randomization between groups. Useful, but less certain than a randomized trial. Prevalence of MAFLD Among Nurses and the Role of Intermittent Fasting (2023-05-30) ♡
- Clinical trialiResearch in patients, without randomization between groups. Useful, but less certain than a randomized trial. NMR-based Metabolic Profiling Identifies High Risk of MAFLD Patients With Advanced Fibrosis (2023-02-21) ♡
- Clinical trialiResearch in patients, without randomization between groups. Useful, but less certain than a randomized trial. Relationship Between MAFLD and Liver Fibrosis Progression in Patients With Chronic Hepatitis B: a Multicenter Retrospective Cohort Study (2023-02-01) ♡
- Laboratory or animal researchiNo research in humans yet. Promising in a test tube or in mice unfortunately means nothing for patients. Pluchea indica Leaf Extract Alleviates Dyslipidemia and Hepatic Steatosis by Modifying the Expression of Lipid Metabolism-Related Genes in Rats Fed a High Fat-High Fructose Diet. (2022/12/31) ♡
- Low-Dose Administration of Cannabigerol Attenuates Inflammation and Fibrosis Associated with Methionine/Choline Deficient Diet-Induced NASH Model via Modulation of Cannabinoid Receptor. (2022/12/30) ♡
- Correlation of Metabolic Syndrome with Redox Homeostasis Biomarkers: Evidence from High-Fat Diet Model in Wistar Rats. (2022/12/30) ♡
- Review articleiA summary of what is known about a topic, written by experts. Not compiled according to fixed search rules, so the selection of studies may be biased. Pectin in Metabolic Liver Disease. (2022/12/29) ♡
- ALS-L1023 from Melissa officinalis Alleviates Liver Fibrosis in a Non-Alcoholic Fatty Liver Disease Model. (2022/12/29) ♡
- Bempedoic Acid Restores Liver H (2) S Production in a Female Sprague-Dawley Rat Dietary Model of Non-Alcoholic Fatty Liver. (2022/12/28) ♡
- Interaction between the PNPLA3 Gene and Nutritional Factors on NAFLD Development: The Korean Genome and Epidemiology Study. (2022/12/28) ♡
- Associations between red blood cell count and metabolic dysfunction-associated fatty liver disease (MAFLD). (2022/12/27) ♡
- Experimental non-alcoholic fatty liver disease causes regional liver functional deficits as measured by the capacity for galactose metabolism while whole liver function is preserved. (2022/12/27) ♡
- Exercise-Induced ADAR2 Protects against Nonalcoholic Fatty Liver Disease through miR-34a. (2022/12/27) ♡
- Sleeve gastrectomy improves lipid dysmetabolism by downregulating the USP20-HSPA2 axis in diet-induced obese mice. (2022/12/27) ♡
- UPLC-QTOF-MS Based Comparison of Rotundic Acid Metabolic Profiles in Normal and NAFLD Rats. (2022/12/26) ♡
codex.care does not provide medical advice. Always discuss symptoms, medication, and treatment choices with your own healthcare provider.